Everything below concerns Fifteen residues. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
In 2024, the United Nations General Assembly adopted the first global resolution on the promotion of "safe, secure and trustworthy" AI systems that emphasized the respect, protection and promotion of human rights in the design, development, deployment and the use of AI. In May 2024, the Department for Science, Innovation and Technology (DSIT) announced £8.5 million in funding for AI safety research under the Systemic AI Safety Fast Grants Programme, led by Christopher Summerfield and Shahar Avin at the AI Safety Institute, in partnership with UK Research and Innovation. Technology Secretary Michelle Donelan announced the plan at the AI Seoul Summit, stating the goal was to make AI safe across society and that promising proposals could receive further funding. The UK also signed an agreement with 10 other countries and the EU to form an international network of AI safety institutes to promote collaboration and share information and resources. Additionally, the UK AI Safety Institute planned to open an office in San Francisco. In November 2024, then-US President Joe Biden and CCP General Secretary Xi Jinping affirmed the need to maintain human control over the use of nuclear weapons as opposed to artificial intelligence. As part of the National Defense Authorization Act for Fiscal Year 2025, Congress enacted the section 1638, "Sense of Congress with respect to use of artificial intelligence to support strategic deterrence", into the US Code of federal law.
=== Acid hydrolysis === Acid hydrolysates are produced from various edible protein sources, with soy, corn, wheat, and casein being the most common. For the production of aHVP, the proteins are hydrolyzed by cooking with a diluted (15–20%) hydrochloric acid, at a temperature between 90 and 120 °C for up to 8 hours. After cooling, the hydrolysate is neutralized with either sodium carbonate or sodium hydroxide to a pH of 5 to 6. During hydrolysis, extraneous polymeric material known as humin, which forms from the interaction of carbohydrate and protein fragments, is generated and subsequently removed by filtration and then further refined. The source of the raw material, concentration of the acid, the temperature of the reaction, the time of the reaction, and other factors can all affect the organoleptic properties of the final product. Activated carbon treatment can be employed to remove both flavor and color components, to the required specification. Following a final filtration, the aHVP may, depending upon the application, be fortified with additional flavoring components. Thereafter, the product can be stored as a liquid at 30–40% dry matter, or alternatively it may be spray dried or vacuum dried and further used as a food ingredient. One hundred pounds (45 kg) of material containing 60% protein will yield 100 pounds of aHVP, which contains approximately 40 pounds (18 kg) of salt. This salt gain occurs during the neutralization step.
=== Types === A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs and deaminate them to inosine. Inosines are recognised as guanosine by the cell's translational machinery. There are three members of the ADAR family ADARs 1-3 with ADAR 1 and ADAR 2 being the only enzymatically active members. ADAR3 is thought to have a regulatory role in the brain. ADAR1 and ADAR 2 are widely expressed in tissues while ADAR 3 is restricted to the brain. The double stranded regions of RNA are formed by base-pairing between residues in the close to region of the editing site with residues usually in a neighboring intron but can be an exonic sequence. The region that base pairs with the editing region is known as an Editing Complentary Sequence (ECS). It is thought that the pre-mRNA of IGFBP7 is a substrate for ADAR1 based on the expression spectrum of the editing enzyme.
The Organisation for Economic Co-operation and Development (OECD; French: Organisation de coopération et de développement économiques, OCDE) is an intergovernmental organisation with 38 member countries. It was founded in 1961 to stimulate economic progress and world trade. The OECD is a forum whose member countries describe themselves as committed to democracy and the market economy, providing a platform for collective problem-solving, analysis, and coordination. In 2026, their collective population was 1.38 billion people with high levels of human development. As of 2026, OECD member countries collectively comprised 58.4% of global nominal GDP and 38.9% of global GDP at purchasing power parity. The OECD is an official United Nations observer. Member states have strong social security systems. The OECD is headquartered at the Château de la Muette in Paris, France. The OECD is funded by contributions from member countries and publishes annual reports on economic data as well as a variety of evaluations and rankings.
Haem-using haem peroxidase and the related animal heme-dependent peroxidases DyP-type peroxidase family Catalase Manganese peroxidase some haloperoxidase Di-haem cytochrome c peroxidase Non-heme Thiol: glutathione peroxidase, peroxiredoxin vanadium bromoperoxidase Alkyl hydroperoxide reductase NADH peroxidase
Sources: en.wikipedia.org
This phenomenon further promotes heterogeneity and produces a gradient in the microenvironment that fosters the positive selection of a drug-resistant cell population, where cells sensitive to treatment decrease in population size . Plasticity in tumor cells has, additionally, been recognized as a byproduct of tumor heterogeneity and a major contributor to resistance. Tumor cells have the ability to gain stem-like traits in response to changes in their microenvironment, allowing for the survival of cell populations, which ultimately promotes resistance through selection. Tumor cell plasticity is a notable mechanism of acquired resistance. In order to assess the potential reversibility of plasticity in tumor cells, mathematical models informed by tumor heterogeneity and inter-cellular differences have been created. Cellular heterogeneity describes the recently studied phenomenon of genetically identical cells varying in phenotype, cellular response, and drug sensitivity. Cell-to-cell response variability has been attributed to random, stochastic biochemical processes that facilitate protein expression. These intracellular biochemical fluctuations create variation in genetically identical cells by producing unique proteomes and subsequently differing phenotypic responses to drugs even within the same environment.
=== Regulation of reactivity of monomer === To modulate the reactivity between monomer and growing polymeric chain is another approach to enhance sequence control. The rationale for this method is that monomer has to be activated with first catalyst at beginning as a dormant species, which could then participate into polymerization as the second catalyst is introduced. A real example is utilization of HI as first catalyst and ZnI2 as second catalyst to achieve sequence-controlled polymerization of vinyl ethers and styrene derivatives.
In a meta-analysis of various trials involving fluoxetine (Prozac), fluvoxamine (Faverin/Luvox), and sertraline (Zoloft) to test their relative efficacies in treating OCD, clomipramine was found to be significantly more effective. Other studies have borne similar results even when risk of bias is eliminated. A potentially significantly greater inherent side-effect profile, however, makes it a second-line choice in the treatment of OCD. SSRIs are generally better-tolerated but appear to be inferior in terms of actual clinical efficacy.
=== Other names === GAR-936 Tygacil Tigeplug (marketed by Biocon, India) Tigilyn (Marketed by Real Value therapy pharmaceuticals company in Myanmar, Manufactured by Lyka) TIGILITE (marketed in INDIA, Scutonix Lifesciences, Bombay)
The Military Religious Freedom Foundation received more than 200 complaints from 50 military installations, and said that such statements are a violation of the Uniform Code of Military Justice (UCMJ) and reflect Secretary Hegseth's leadership. Multiple members of Congress are requesting an investigation into the DoD over the statements alleged to have been made by several military commanders using biblical references and claiming that the president was anointed by Jesus. The members included Rep. Chrissy Houlahan D-PA, the ranking member of the House Armed Services Subcommittee on Military Personnel. A letter they sent to the military Inspector General stated, "If accurate, these outrageous statements—justifying a war based on interpretations of biblical prophecies, and informing troops that they are risking their lives to advance a specific religious vision—raises not only glaring Constitutional concerns, but potential violations of Department of Defense regulations regarding religious neutrality and breaches of professional obligations and standards expected of military leadership." The complaint asks to determine: if military commanders made the statements and if so, where did statements first originate in the chain of command; did the statements violate DoD Instruction 1300.17 on religious freedom; how widespread were the comments within the military; did service members fear retaliation for reporting the comments; what guidance and training exists to ensure compliance with the DoD policy; and what action should be taken against personnel who violated the policy.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.